Frontlight ResearchEarly access
Myeloproliferative neoplasms trials in Brazil
5 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Where
- Barretos, Curitiba, Florianópolis, Goiânia
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00 - Phase 4CompletedAsciminib Roll-over Study
- Where
- Rio de Janeiro, São Paulo
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 3Not yet taking people in BrazilA Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Where
- Florianópolis, Jaú, Joinville, Porto Alegre, Rio de Janeiro, São Paulo
- Age
- 18 years and over
- People
- 324 worldwide
- Run by
- Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00 - Phase 3Taking peopleINTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
- Where
- Belém, Blumenau, Santa Catarina
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07429266 · EU 2025-524669-25-00 - Phase 2Taking peopleA Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
- Where
- Porto Alegre, São Paulo
- Age
- 18 years and over
- People
- 135 worldwide
- Run by
- Takeda
See details and how to joinNCT05037760 · EU 2023-507468-38-00